Esophageal Squamous Cell Carcinoma, Oligometastatic Disease
Conditions
Keywords
esophageal cancer; oligometastases; PD-1; SBRT
Brief summary
The goal of this phase II clinical trial is to explore the efficacy and safety of anti-PD1 combined with stereotactic body radiation therapy (SBRT) for patients with oligometastatic esophageal squamous cell carcinoma. Participants will receive anti-PD1 and SBRT to the metastatic lesions which are amenable to the delivery of SBRT after 4\ 6 cycles of systemic chemotherapy and anti-PD-1.
Interventions
DRUGPD-1 combined with SBRT
Anti-PD1 monoclonal antibody combined with SBRT. The SBRT defined as the radiation prescription with single dose equal or over 4Gy and the fractions less or equal to 10 fractions. BED equal or over 50Gy is required.
Sponsors
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
1. Eastern Cooperative Oncology Group performance status ≤ 2; 2. Histologically confirmed squamous cell carcinoma of the esophagus; 3. Diagnosed with stage IVB disease (according to UICC TNM version 8) with less than five metastatic lesions within three organs; 4. Received 4 to 6 cycles of standard chemotherapy (fluoropyrimidine or taxane-based platinum doublet chemotherapy) and anti-PD1 treatment, and no progression disease was confirmed; 5. At least one metastatic lesions amenable to the delivery of SBRT; 6. Estimated life expectancy \>4 months; 7. The function of important organs meet the following requirements: a. white blood cell count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥ 1.5×109/L; b. platelets ≥ 100×109/L; c. hemoglobin ≥ 9g/dL; d. serum albumin ≥ 2.8g/dL; e. total bilirubin ≤ 1.5×ULN, ALT, AST and/or AKP ≤ 2.5×ULN; f. serum creatinine ≤ 1.5×ULN or creatinine clearance rate \>60 mL/min; 8. Ability to understand the study and sign informed consent.
Exclusion criteria
1. Progression was confirmed after completion of 4 to 6 cycles of standard chemotherapy and anti-PD1 treatment; 2. Patients with intracranial metastasis disease at diagnosis; 3. History of thoracic irradiation; 4. Known or suspected allergy or hypersensitivity to monoclonal antibodies and the chemotherapeutic drugs: Capecitabine, paclitaxel, or platinum; 5. Patients have spinal bone metastases combined with spinal cord compression; 6. A history of malignancies other than esophageal cancer before enrollment, excluding non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer; 7. Patients who cannot tolerate radiotherapy due to severe cardiac, lung, liver, or kidney dysfunction, or hematopoietic disease or cachexia; 8. Inability to provide informed consent due to psychological, familial, social, and other factors; 9. Female patients who are pregnant or during lactation; 10. Active autoimmune diseases, a history of autoimmune diseases (including but not limited to these diseases or syndromes, such as colitis, hepatitis, hyperthyroidism), a history of immunodeficiency (including a positive HIV test result), or other acquired or congenital immunodeficiency diseases, a history of organ transplantation or allogeneic bone marrow transplantation; 11. A history of interstitial lung disease or non-infectious pneumonia; Presence of active hepatitis B (HBV DNA ≥ 2000 IU/mL or 104 copies/mL), hepatitis C (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of the assay).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 1-year progression-free survival | From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 12 months | 1-year progression-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1-year overall survival | From date of randomization until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 12 months | 1-year overall survival |
| ORR | 3 months after SBRT (plus or minus 14 days)] | Overall response rate |
| Treatment-related adverse events | From the start of treatment to 2 year after the completion of treatment | Toxicity of treatment was evaluated according to CTCAE 4.0 |
Countries
China
Contacts
Primary ContactMian Xi, MD
Backup ContactBaoqing Chen, MD
Outcome results
None listed